Mission
At Ropana Vascular, we develop endovascular devices to fill significant unmet clinical needs in the treatment of cardiovascular disease.
Vision - Reduce Amputations
Peripheral Arterial Disease (PAD)
PAD affects > 200 Million patients worldwide and over 12 million in the United States.
Solving a Major Unmet Medical Need
Peripheral CTOs (Chronic Total Occlusions) are common in advanced PAD, with high failure rates in crossing.
CLTI (Chronic Limb Threatening Ischemia) is the most advanced and serious form of PAD.
Clinicians need a safer, more effective, less traumatic, and time saving crossing option.
Ropana Vascular's FirstPass IVL Catheter is being designed with the CTO in mind!
FirstPass*
IVL technology created as a time saving choice for crossing CTOs more efficiently and less traumatically.
*Currently under development - not FDA cleared
Under Development
Based on functional testing and visual inspection, our end-emitting lithotripsy catheter successfully crossed both gypsum and human calcified plaque.
Next Phase
Exit Strategy
Currently refining prototype with human artery testing (on amputated legs) and ongoing development of console/generator.
Additional sizes for above and below the knee applications.
Strategic work on patents - provisional and applied
Exit Strategy
Exit Strategy
Commercialize to profitability, disruption, and exit options.
FDA clearance - Go to market
- Commercialization leadership team is already in place.
- Revenue ramp focus on capturing growing peripheral CTO/IVL market, specifically in OBLs and ASCs.
Leadership Team
Vijay
Robert
Vijay
Vijay Ramanath, MD, FACC, FSCAI
Ropana Vascular Founder
Interventional Cardiologist with 15+ years of clinical expertise, with an entrepreneurial mindset and multiple patents.
James
Robert
Vijay
James Lowry
Ropana Vascular CEO
35 years of leadership in medical device sales, marketing and consulting to startups, scaleups and global corporations.
Robert
Robert
Robert
Robert Dorsher, MBA
Ropana Vascular COO
40 years of medical device leadership in strategic commercialization, operations and planning.